Aegera Initiates Fifth Phase I/II Cancer Trial

Aegera Therapeutics has dosed the first patient in its fifth Phase I/II clinical oncology study of AEG35156 for treating multiple cancers.

Partially funded by The Leukemia & Lymphoma Society, the study’s primary goal is to determine the recommended dose, safety profile and response rate of the drug in patients with relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma.

The drug is intended to lower the apoptotic threshold of cancer cells, enhancing their sensitivity to intrinsic death and chemotherapy without harming healthy cells, Aegera said.